BACKGROUND: Juvenile polyps are distinct hamartomatous malformations of the gastrointestinal tract that may occur in the heritable juvenile polyposis syndrome (JPS) or sporadically. Histologically, juvenile polyps are characterized by a marked increase of the stromal cell compartment, but an epithelial phenotype has also been reported. JPS has an increased risk of colorectal cancer but sporadic juvenile polyps do not. In 50% to 60% of patients with JPS, a germline mutation of the transforming growth factor-β/bone morphogenetic protein (BMP) pathway genes SMAD4 or BMPR1A is found. This study compares the histologic phenotype of juvenile polyps with a SMAD4 or BMPR1A germline mutation and sporadic juvenile polyps. METHODS: Hematoxylin and Eosin-stained slides of 65 JPS polyps and 25 sporadic juvenile polyps were reviewed for histologic features and dysplasia. Systematic random crypt and stroma counts were obtained by count stereology, and a crypt-stroma ratio was determined. All polyps were subsequently categorized as type A (crypt-stroma ratio <1.00) or type B (crypt-stroma ratio ≥1.00), the latter referring to the epithelial phenotype. Cell cycle activity was assessed using immunohistochemistry ofthe proliferation marker Ki67, and mutation analysis was carried out for KRAS and APC to determine the involvement of the adenoma-carcinoma sequence. RESULTS: Juvenile polyps with a SMAD4 germline mutation were predominantly type B, whereas type A was more common among juvenile polyps with a BMPR1A germline mutation. However, this distinction could not be ascribed to differences in cell cycle activity. Dysplasia was equally common in JPS polyps with either a SMAD4 or BMPR1A germline mutation, in which the involvement of the adenoma-carcinoma sequence does not seem to play a distinct role. CONCLUSION: Juvenile polyps in the setting of JPS exhibit distinct phenotypes correlating with the underlying genetic defect.
BACKGROUND:Juvenile polyps are distinct hamartomatous malformations of the gastrointestinal tract that may occur in the heritable juvenile polyposis syndrome (JPS) or sporadically. Histologically, juvenile polyps are characterized by a marked increase of the stromal cell compartment, but an epithelial phenotype has also been reported. JPS has an increased risk of colorectal cancer but sporadic juvenile polyps do not. In 50% to 60% of patients with JPS, a germline mutation of the transforming growth factor-β/bone morphogenetic protein (BMP) pathway genes SMAD4 or BMPR1A is found. This study compares the histologic phenotype of juvenile polyps with a SMAD4 or BMPR1A germline mutation and sporadic juvenile polyps. METHODS:Hematoxylin and Eosin-stained slides of 65 JPS polyps and 25 sporadic juvenile polyps were reviewed for histologic features and dysplasia. Systematic random crypt and stroma counts were obtained by count stereology, and a crypt-stroma ratio was determined. All polyps were subsequently categorized as type A (crypt-stroma ratio <1.00) or type B (crypt-stroma ratio ≥1.00), the latter referring to the epithelial phenotype. Cell cycle activity was assessed using immunohistochemistry ofthe proliferation marker Ki67, and mutation analysis was carried out for KRAS and APC to determine the involvement of the adenoma-carcinoma sequence. RESULTS:Juvenile polyps with a SMAD4 germline mutation were predominantly type B, whereas type A was more common among juvenile polyps with a BMPR1A germline mutation. However, this distinction could not be ascribed to differences in cell cycle activity. Dysplasia was equally common in JPS polyps with either a SMAD4 or BMPR1A germline mutation, in which the involvement of the adenoma-carcinoma sequence does not seem to play a distinct role. CONCLUSION:Juvenile polyps in the setting of JPS exhibit distinct phenotypes correlating with the underlying genetic defect.
Authors: M G Sayed; A F Ahmed; J R Ringold; M E Anderson; J L Bair; F A Mitros; H T Lynch; S T Tinley; G M Petersen; F M Giardiello; B Vogelstein; J R Howe Journal: Ann Surg Oncol Date: 2002-11 Impact factor: 5.344
Authors: Danielle Langeveld; W Arnout van Hattem; Wendy W J de Leng; Folkert H Morsink; Fiebo J W Ten Kate; Francis M Giardiello; G Johan A Offerhaus; Lodewijk A A Brosens Journal: Clin Cancer Res Date: 2010-08-03 Impact factor: 12.531
Authors: J R Howe; J L Bair; M G Sayed; M E Anderson; F A Mitros; G M Petersen; V E Velculescu; G Traverso; B Vogelstein Journal: Nat Genet Date: 2001-06 Impact factor: 38.330
Authors: K L Woodford-Richens; A J Rowan; R Poulsom; S Bevan; R Salovaara; L A Aaltonen; R S Houlston; N A Wright; I P Tomlinson Journal: Am J Pathol Date: 2001-10 Impact factor: 4.307
Authors: Peter Hohenstein; Lia Molenaar; Joyce Elsinga; Hans Morreau; Heleen van der Klift; Ada Struijk; Shantie Jagmohan-Changur; Ron Smits; Henk van Kranen; Gert-Jan B van Ommen; Cees Cornelisse; Peter Devilee; Riccardo Fodde Journal: Genes Chromosomes Cancer Date: 2003-03 Impact factor: 5.006
Authors: Xi C He; Jiwang Zhang; Wei-Gang Tong; Ossama Tawfik; Jason Ross; David H Scoville; Qiang Tian; Xin Zeng; Xi He; Leanne M Wiedemann; Yuji Mishina; Linheng Li Journal: Nat Genet Date: 2004-09-19 Impact factor: 38.330
Authors: Anna-Pavlina G Haramis; Harry Begthel; Maaike van den Born; Johan van Es; Suzanne Jonkheer; G Johan A Offerhaus; Hans Clevers Journal: Science Date: 2004-03-12 Impact factor: 47.728
Authors: K Woodford-Richens; J Williamson; S Bevan; J Young; B Leggett; I Frayling; Y Thway; S Hodgson; J C Kim; T Iwama; M Novelli; D Sheer; R Poulsom; N Wright; R Houlston; I Tomlinson Journal: Cancer Res Date: 2000-05-01 Impact factor: 12.701
Authors: Lodewijk Aa Brosens; Danielle Langeveld; W Arnout van Hattem; Francis M Giardiello; G Johan A Offerhaus Journal: World J Gastroenterol Date: 2011-11-28 Impact factor: 5.742